Platelet release system and platelet release method
The system addresses inefficiencies in existing platelet production systems by using a reservoir with controlled fluid flow and vortex disturbances to achieve high flow rates and efficient platelet release on an industrial scale, overcoming scalability and contamination issues.
Patent Information
- Application Number
- JP2022519721
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-10-11
- Filing Date
- 2020-10-12
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2040-10-12
AI Technical Summary
Current systems for in vitro platelet production, such as microfluidic and reservoir systems, face limitations in efficiency and scalability, with low flow rates and complexity, and often require chemical fixation methods that are not suitable for large-scale operations.
A system comprising a platelet release reservoir with specific fluid connection elements and a pumping device that generates a continuous flow and vortex disturbances to fragment cytoplasmic extensions of megakaryocytes, mimicking the natural process of platelet release, allowing high flow rates and efficient platelet production on an industrial scale.
The system achieves high flow rates of several liters per hour, efficiently releasing platelets comparable to manual pipetting methods, with improved scalability and reduced contamination risks, suitable for industrial applications.
Smart Images

Figure 0007584508000001 
Figure 0007584508000002 
Figure 0007584508000003
Abstract
Description
[Technical field]
[0001] The present invention relates to a system for the release of platelets from a fluid containing megakaryocyte progenitor cells, megakaryocyte cells containing cytoplasmic extensions in particular. The present invention also relates to an assembly for supplying a number of systems such as the aforementioned systems. Finally, the present invention relates to a method for the continuous release of platelets by such a system. The present invention is more particularly adapted for the in vitro production of platelets on an industrial scale. [Background technology]
[0002] In vitro production of platelet release meets the growing demand for various medical applications. Currently, there are essentially two categories of systems intended for such specific purposes: microfluidic systems and "reservoir" systems. The category of systems intended for platelet release stems from findings made in situ that indicate the need for flow.
[0003] An example of a reservoir system is described in the patent application WO 2005 / 023363. This system is provided with means for agitating the fluid to be treated. It comprises a reservoir, in particular for a fluid containing megakaryocyte cells, and at least one means for agitating the fluid, whereby the release of platelets occurs. This agitation occurs within the reservoir itself, for example by means of a vertical reciprocating paddle. The main drawback of such a system is that it is not adapted to operate under conditions that guarantee the quality of the platelets obtained as described above. The reason for this is that the platelets are not isolated from the external environment and from sources of contamination present in said environment, making them unsuitable for medical use.
[0004] Microfluidic systems, as the name suggests, are generally systems of micrometer dimensions (tens of microns up to hundreds of microns) that contain a network of reservoirs and channels interconnected in specific arrangements to perform distinct functions. Classically, these systems comprise a site dedicated to megakaryocyte cells and megakaryocytes culture, and optionally platelet release, connected to a network of channels configured for platelet extraction / recovery. These systems, the majority of which are biomimetic, attempt to mimic the physiological environment in order to increase platelet production.
[0005] Due to their small size, these microfluidic systems have two inherent limitations. First, the platelet flow rates that can be achieved by these systems are low, typically a few hundred microliters per hour (μL / h). As an example, a system with a flow rate of 200 μL / h would require 50,000 hours, or 5.7 years, to process 10 L of fluid. To achieve the same total flow rate, multiple systems would need to be connected in parallel. However, the number of systems required in the above example would be very large, 50,000 systems, further increasing the system complexity. Even in the best case scenario, such systems are only suitable for fluid samples of a fairly limited volume.
[0006] Secondly, all microfluidic devices described in the literature implement mechanisms / methods to "fix" megakaryocytes and thus extract platelets, the immobilization phase of which is often based on the use of drugs or chemical coating compounds, which is a drawback.
[0007] Recently, a new method has been developed to release platelets from megakaryocyte cells using pipetting. Such a method is described in Non-Patent Document 1. In such a method, the process for releasing platelets is a direct result of pipetting. The pipetting is similar to conventional pipetting in that a sample of the culture medium containing megakaryocyte cells is taken with the pipette, except that the pipetting is repeated as many times as necessary to create the agitation conditions required for the release of platelets. As a result of this method, platelets were detected in the processed fluid, verifying the ability of the pipetting to release platelets and making the pipetting very easy to implement. However, this method is not suitable for large-scale operations. This is because pipetting is originally a manual operation and is therefore only suitable for processing limited volumes of fluid. [Prior art documents] [Patent documents]
[0008] [Patent Document 1] International Publication WO201909364(A1) [Non-patent literature]
[0009] [Non-Patent Document 1] Strassel et al. “Aryl hydrocarbon receptor-dependent enrichment of a high potential to produce propalets”,Blood,May 5,2016,vol.127,no18 Summary of the Invention
[0010] The present invention makes it possible to overcome the aforementioned drawbacks and finally proposes a system for releasing platelets from a fluid containing, in particular, megakaryocyte cells containing cytoplasmic extensions, said system comprising: - a device, a platelet release reservoir having a first opening and a second opening; a first fluid connection element attached at the level of the first opening and adapted to inject the fluid into the reservoir, the first fluid connection element having an opening for injecting fluid into the platelet releasing reservoir and a portion narrowing towards the opening, with a sudden expansion in cross section between the injection opening and the reservoir; a second fluid connection element attached at the level of the first opening, the second fluid connection element having an opening for discharging a fluid; - a device for pumping a fluid in fluid communication with a reservoir by means of a second fluid connection element or a first fluid connection element; - a power supply module for a pumping device, - a programming system configured to control a power supply module for the pumping device to implement one or more platelet release sequences designed to generate a continuous flow of fluid between the inlet opening and the outlet opening and a vortex disturbance in the reservoir that fragments cytoplasmic extensions of megakaryocyte cells; It is equipped with:
[0011] The system according to the invention is therefore configured to reproduce the pipetting process performed manually with a pipette, thus allowing a continuous and automatic release of platelets.
[0012] Even more remarkable is the fact that the invention is practiced on a large scale: the geometry of the system according to the invention allows for the processing of large volumes of fluid at high flow rates (on the order of several liters per hour), making the system particularly suitable for use on an industrial scale.
[0013] In addition, the system allows obtaining a number of platelets released from megakaryocyte cells that is at least comparable to the platelets obtained by manual pipetting, making the system have a particularly high platelet release efficiency. This is achieved mainly due to the synergistic effect of the geometry of the elements of the system, in particular the conical shape of the first fluid connection element, in combination with the large dimensions of the reservoir, and the flow rate generated by the pumping device, which allows the generation of vortex disturbances with the size of the megakaryocytes in the reservoir.
[0014] According to various features of the invention, which may be taken together or separately, - The constriction is conical in shape, - the first connection element includes a longitudinal axis and the second connection element includes a longitudinal axis, the longitudinal axes being either intersecting or parallel and thus separated by a non-zero distance d; - the injection opening has an opening diameter of less than 1 mm; - the ratio of the opening diameter of the injection opening to the cross-sectional width of the reservoir is 0.02 to 0.1; - the ratio of the opening diameter of the injection opening to the cross-sectional width of the reservoir is 0.05; - the discharge opening has an opening diameter of less than 1 mm, and the ratio of the opening diameter of the discharge opening to the cross-sectional width of the reservoir is 0.02 to 0.1; - the ratio of the diameter of the discharge opening to the width of the cross section of the reservoir is 0.05: - the reservoir has a spherical shape; - the system comprises a source reservoir for storage of fluid, the reservoir being connected to a first fluid connection element for supplying the reservoir for platelet release; - the system comprises a reservoir for receiving a fluid, connected to a second fluid connection element for collecting said fluid intended to be aspirated from the reservoir for platelet release; - a pumping device is placed in the receiving reservoir; - the second connection element further comprises a portion extending from the opening for discharging fluid towards a pumping device; The system includes one other device, the other device being: a platelet release reservoir having a first opening and a second opening; a first fluid connection element mounted at the level of the first opening and adapted to inject the fluid inside the reservoir, the first fluid connection element comprising an opening for injecting a fluid and a first constriction for allowing a fluid to accumulate, the first constriction opening onto the injection opening; a second fluid connection element attached at the level of the second opening, the second fluid connection element having an opening for discharging fluid; the other device is disposed in parallel with the first device and is connected to the pumping device by a second device of the other device; - the system comprises another device, the other device being a platelet release reservoir having a first opening and a second opening; a first fluid connection element mounted at the level of the first opening and adapted to inject the fluid inside the reservoir, the first fluid connection element comprising an opening for injecting the fluid and a first constriction for enabling the acceleration of the fluid, the first constriction opening onto the injection opening; a second fluid connection element attached at the level of the second opening, the second fluid connection element having an opening for discharging fluid; The other device is arranged in series with the first device, and the second connection element of the other device is in fluid communication with the first fluid connection element of the first device.
[0015] The present invention further relates to a method for releasing platelets from a fluid containing megakaryocyte cells, in particular those containing cytoplasmic extensions, the method being carried out by a system as described above and comprising the following steps: (100) Providing a fluid containing megakaryocytes suspended in the fluid, the megakaryocytes comprising cytoplasmic extensions; (200) Providing power to a pumping device; (300) controlling a programming system to initiate one or more platelet release sequences; The or each platelet release sequence is performed to generate a continuous flow of fluid between the inlet and outlet openings and to generate vortex disturbances within the reservoir so as to cause fragmentation of cytoplasmic extensions of megakaryocyte cells.
[0016] Advantageously, during step (200), a relative vacuum is generated in the device that is between -10 kPa and -50 kPa.
[0017] Further objects, features and advantages of the present invention will become more apparent from the following description when taken in conjunction with the accompanying drawings. [Brief description of the drawings]
[0018] [Figure 1a] 1 is a schematic diagram of a system according to a first embodiment of the invention, in which a reservoir for fluid is shown in cross-section in side view; [Figure 1b] FIG. 1b is a schematic diagram of an alternative embodiment of the system of FIG. [Figure 1c] FIG. 1b is an enlarged view of a reservoir with the system shown in FIG. [Figure 2a] FIG. 2 is a schematic diagram of a system according to a second embodiment of the invention, comprising a number of devices connected in series. [Figure 2b] 1 shows an exploded view of a system according to the invention, comprising five devices connected in series. [Figure 2c] 2a and 2b, which is now connected to a source reservoir and a reservoir for receiving a fluid. [Figure 2d]FIG. 5 is a schematic diagram of an assembly according to a third embodiment of the invention, comprising multiple devices connected in parallel. [Figure 3a] FIG. 1 is a schematic diagram of a method according to the present invention. [Figure 3b] FIG. 3b is a schematic diagram of the method of FIG. 3a, showing the substeps for carrying out the method. [Figure 4a] Precursor platelet megakaryocyte cells are shown. [Figure 4b] 1 shows platelets obtained after the platelet release method according to the present invention. [Figure 5a] FIG. 1 is a comparative diagram showing the efficiency of platelet release obtained by using a pipette and by using a system according to the invention as a function of the relative vacuum within the system. [Figure 5b] Analysis of platelet functionality obtained at a pressure of -30 kPa for natural platelets (hollow rods) and cultured platelets (solid rods). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0019] With reference to Figures 1a to 1c, the present invention relates to a system 1 for releasing (or liberating) platelets P from a fluid F containing megakaryocyte cells Mk.
[0020] The fluid F in question is a medium containing a population of cells obtained from immortalized or non-immortalized cell lines at different stages of differentiation, including, for example, megakaryocyte progenitor cells, megakaryocytes. Megakaryocytes or megakaryocytic cells are large blood cells (up to 100 μm, 30 μm in culture medium) which, at maturity, have long cytoplasmic extensions or proplatelets called proplatelets.
[0021] The mechanisms involved in the formation of platelets are still the subject of much research. In particular, platelet release occurs during the process of fragmentation of Mk megakaryocytes and / or cytoplasmic extensions Ck into platelets. This is a highly accentuated in vivo process that occurs naturally in blood due to the force of blood flow. Megakaryocytes Mk play a crucial role since they are progenitor cells. However, the process of platelet release in the body remains largely unexplained and many questions still exist about the exact role of blood flow in transendothelial passage and formation of platelets. This process has been reproduced in vitro by microfluidic systems and some in vivo mechanisms could be demonstrated by microfluidic experiments. This process can also be reproduced in vitro manually by pipettes or by devices such as those presented in the introduction of this specification. Furthermore, this process allows a good understanding of the mechanisms involved in the release of platelets (Strassel et al. 2016). The production of platelets in vitro provides a good understanding of the mechanisms involved in the formation of platelets. In general, however, the efficiency of platelet release is lower than that obtained in vivo. The device proposed according to the invention makes it possible to mimic the platelet release process by manual pipetting as disclosed by Strassel et al., without reproducing the reciprocating movements occurring during pipetting, which are replaced by a continuous movement using the system 1. The invention therefore aims to reproduce the fragmentation process of megakaryocytes Mk and / or cytoplasmic extensions Ck on an industrial scale, making it possible to process large volumes of fluid F (several liters per hour).
[0022] The system 1 according to the invention comprises a device 2, a pumping device 60 and a programming system 70, which will be described in the following sections.
[0023] The device 2 comprises a platelet release reservoir 10 , a first fluid connection element 20 and a second fluid connection element 30 .
[0024] The reservoir 10 for platelet release (hereinafter referred to as "reservoir 10") has a longitudinal dimension of millimeters to centimeters, i.e. a longitudinal dimension of 1 mm to several cm. For comparison, the minimum dimension of the reservoir 10 of the system 1 according to the invention is the maximum dimension of a conventional microfluidic system. This makes the reservoir 10 a larger reservoir and a larger capacity than known microfluidic systems.
[0025] In the exemplary embodiment shown in FIG. 1a, the reservoir 10 is spherical in shape. This reservoir 10 comprises a spherical wall 12 that defines a cavity 14 in which the fluid F can circulate. The cavity, in addition to being a zone for the circulation of the fluid F, is a region that provides for the formation of turbulent flow of the fluid F. This means that it provides for the formation of vortex disturbances of a size at least equal to the size of the megakaryocytes Mk. In other words, the cavity 14 is configured, as mentioned above, on the one hand by its dimensions and on the other hand by its internal volume, so as to provide for the formation of vortex disturbances therein. However, the reservoir 10 may be of any other shape, for example, a parallelepiped, a cylinder, etc. The most important thing is that the reservoir 10 comprises a cavity 14 of sufficient dimensions to provide for the formation of vortex disturbances. For example, for the fluid F containing the megakaryocytes Mk, as the reader has already confirmed, the size of the megakaryocytes Mk can reach 30 μm in the culture medium. The cavity 14 therefore has larger dimensions (millimeters to centimeters) since this fluid F contains a large number of megakaryocyte cells Mk, for example hundreds or even thousands.
[0026] The wall 12 comprises at least a first opening 16 and a second opening 18. The first opening 16 is dedicated to a fluid connection with a first connection element 20, while the second opening 18 is dedicated to a fluid connection with a second connection element 30. Preferably, these form dedicated openings in the wall 12, since the system 1 is closed.
[0027] The first fluid connection element 20 is a means for supplying the fluid F to the reservoir 10. In other words, it is an inlet for the fluid F in the reservoir 10. The first fluid connection element is attached at the level of the first opening 16 of the reservoir 10. It comprises, in this order with respect to the direction of fluid flow, a connecting portion 26, a constriction 24 and an opening (orifice) 22 for the injection of the fluid. The constriction 24 therefore opens onto the injection opening (orifice) 22. For this reason, it should be noted that the connecting portion 26 is not essential, although it will be better understood below. Thus, in the exemplary embodiment shown in FIG. 1a, the first fluid connection element 20 is attached at the level of the first opening 16 by the connecting portion 26, but it may be attached to the reservoir 10 in other configurations. In fact, the first fluid connection element can be very easily attached by the constriction 24 as well as by means of the injection opening 22. In the latter configuration, the injection opening 22 is located at the level of the wall 12, but it will be understood that it can correspond to (i.e. coincide with) the first opening 16 of the reservoir.
[0028] As mentioned above, the portion 24 is narrowed. The portion 24 is narrowed in that it narrows from the connecting portion 26, or alternatively, when the connecting portion 26 is not present, from the end of the first connecting element 20 towards the opening 22 through which the fluid is injected. In other words, the portion 24 narrows in the direction of flow relative to the longitudinal axis X1 of the first connecting element 20 passing through the center of the opening 22. The narrowed shape of the portion 24 makes it possible to accelerate the fluid F by a venturi. Concomitantly, the fluid F entering the reservoir 10 therefore has a higher velocity compared to the fluid entering the system 1 through the portion 24 without the flaring.
[0029] Advantageously, the constriction 24 from the connection portion 26, or alternatively, when the connection portion 26 is not present, from the end of the first connection element 20 towards the opening 22 for the injection of the fluid, may be substantially continuous. The constriction makes it possible to reduce friction and further increases the acceleration of the fluid. In this respect, the constriction 24 may be conical. Advantageously, the use of the conical portion 24 facilitates the connection with tubular (i.e. cylindrical) fluid connection means, many of which are commercially available. By way of example, the portion 24 may have a pyramidal or tetrahedral shape. Most importantly, the constriction 24 narrows from the connection portion 26 of the first connection element 20 towards the opening 22 for the injection of the fluid. In this case, when discharged into the reservoir 10, this fluid F is significantly decelerated due to the difference in cross section that exists between the first fluid connection element 20, in particular the injection opening 22, and the reservoir 10.
[0030] In fact, the injection opening 22 advantageously has an opening diameter of very small size compared to the diameter of the reservoir 10, in the case of the spherical type, but this diameter is equal to or greater than the size of the particles remaining in the reservoir 10 (i.e. platelets P and other products Dk, essentially resulting from the fragmentation of megakaryocytes). Preferably, the opening diameter is less than 1 mm, but on the other hand, as the reader has confirmed, the reservoir 10 has a longitudinal dimension in the range of millimeters to centimeters, which is in any case much larger than the diameter of the opening 22. It should be noted in this respect that the shape of the injection opening 22 is not limited. The important point here is the size of the injection opening 22.
[0031] Therefore, an abrupt cross-sectional expansion exists between the inlet opening 22 and the reservoir 10. This abrupt expansion corresponds to a singularity and gives rise to a singular flow profile of the fluid F. As previously mentioned, the fluid F is accelerated through the inlet opening 22 and out of the constriction 24, and therefore experiences a pressure drop (i.e., slows down) as it passes from the inlet opening 22 to the reservoir due to this singularity. The ratio R of the diameter of the inlet opening 22 to the diameter of the reservoir 10, or more generally the cross-sectional width of the reservoir 10, is EThe smaller R is than 1, the larger the singularity and the larger the pressure drop. This is also true vice versa when the ratio increases. An example of a system 1 according to the invention that has already been put into practice is a reservoir 10 having a diameter equal to 16 mm and a pressure drop equal to 0.8 mm (hence R E In order to increase the platelet release efficiency of the system 1, the ratio R of the opening diameter of the opening 22 to the cross-sectional width of the reservoir of 0.02 to 0.1 is required for the platelet release from the fluid F for the injection opening 22 having an opening diameter of less than 1 mm. E Advantageously, R E is 0.04 to 0.08 for an opening diameter of less than 1 mm. More advantageously, R E is 0.04 to 0.06 for an opening diameter of less than 1 mm. For these reasons, it is even more advantageous to E is equal to 0.05. In fact, in the latter case, the efficiency of the release of platelets is better.
[0032] However, as explained below, the fluid F decelerates as it enters the reservoir 10 and remains in a laminar flow regime in the truest sense of the term (the Reynolds number varies between 0 at the vortex center, whose size is close to that of the reservoir 10, and 1500 at the level (height) of the injection opening 22), but is not stationary within said reservoir 10 due to the fluid displacements generated by the pumping device 60. The reservoir 10 is therefore merely a place through which the fluid F passes, and not a place for storing said fluid F, i.e. where the fluid stagnates during operation of the system 1.
[0033] In this regard, it is noted that in addition to the platelet release reservoir 10, the system 1 may also comprise a source reservoir 40 for storing a fluid F, which is connected to the first fluid connection element 20 in order to supply the reservoir. The fluid F may thus be stored in the source reservoir 40 before passing through the first element 20, although this is not essential. The reservoir 40 is therefore the most upstream element of the system 1 in the direction of flow.
[0034] In addition, the system 1 may also comprise a reservoir 50 for receiving a fluid F. The reservoir 50 for receiving a fluid is connected to a second fluid connection element 30 for collecting said fluid aspirated from the reservoir. In contrast to the source reservoir 40, the receiving reservoir 50 is the most downstream element of the system 1 in the direction of flow. The latter arrangement will be explained hereafter with regard to the second fluid connection element 30.
[0035] Therefore, reservoir 10 is considered to be significant in that system 1 may comprise a source reservoir 40 upstream thereof and a receiving reservoir 50 downstream thereof in the direction of flow.
[0036] The second fluid connection element 30 is then a means for discharging the fluid F outside the reservoir 10, thus forming an outlet channel for the fluid F. It is in fluid communication with the receiving reservoir 50 through one of its ends. In addition, the second fluid connection element is attached at the level of the second opening 18 of the reservoir. It comprises, in order in the direction of flow of the fluid F, an opening (orifice) 32 for discharging the fluid, a discharge part 34 and a connection part 36. The second fluid connection element is similar to the first fluid connection element for the reservoir 10, albeit in a different orientation, and has a similar structure (e.g. the size of the discharge opening (discharge orifice) 32 for the reservoir 10 for platelet release).
[0037] For this reason, the flow geometry is different at the reservoir 10 / discharge opening 32 interface, mainly due to the type of singularity. In contrast to the inlet opening 22 / reservoir 10 interface, the singularity is present in an abrupt narrowing of the cross section in the direction of flow, since the diameter (or, if applicable, the circumference of the reservoir 10) is much larger than the diameter of the discharge opening 32. Taking into account the dimensions of the connecting reservoir 10 and the discharge opening 32, such a singularity further increases the pressure drop experienced by the fluid F as it passes from the reservoir 10 to the second fluid connection element 30. However, this is mitigated by the fluid displacement generated by the pumping device 60, as will be explained in more detail below. This singularity makes it possible to increase the residence time of the fluid inside the reservoir 10, since the abrupt narrowing of the cross section acts as a barrier for the fluid F, which prevents it from quickly leaving the reservoir 10, if not directly from the reservoir. A direct consequence of doing so is to encourage the formation of turbulent or vortex disturbances within the reservoir 10 as the residence time of the fluid F increases.
[0038] Moreover, the residence time of the fluid F inside the reservoir 10 can be advantageously increased further by offsetting the inlet opening 22 with respect to the outlet opening 32. In fact, the inlet opening 22 and the opening 32 are supported by two axes, but in a tilted plane, i.e., the plane is neither horizontal nor vertical, as shown for example in FIG. 1b. In this regard, as shown in FIG. 1c, presented in the enlarged view of the enclosed area R in FIG. 2b, and mentioned above, the first connection element 20 comprises a longitudinal axis X1. The longitudinal axis X1 is the central axis of the first fluid connection element 20 passing through the inlet opening 22. The second fluid connection element 30 then comprises a longitudinal axis X2, which is arranged in a similar manner to the longitudinal axis X1 with respect to the second fluid connection element 30. The two longitudinal axes X1 and X2 may be intersecting or parallel. Advantageously, the longitudinal axes are separated by a non-zero distance d to increase the residence time of the fluid F and to increase the vortex turbulence. This configuration also allows the reservoir 10 to be filled in a "bubble-free" manner. In fact, the fluid F enters through the inlet opening 22 by suction, but once all the air contained in the reservoir 10 has been sucked out, the fluid F leaves through the outlet opening.
[0039] The discharge opening 32 is therefore separated from the inlet opening 22 by a non-zero distance d in the direction of axis Y perpendicular to the longitudinal axes X1 and X2. Preferably, this distance d is between 3 and 4 mm. However, the openings 22, 32 may be separated by the distance d in the direction of axis Y, but they may also be separated by a distance d' in the direction of axis X in the same plane and / or in plane XZ. Axis Z is perpendicular to axis X in the direction of the cross section (out of the plane of the figure). In this, the cross section of FIG. 1c may be misleading since the first and second openings 16 and 18, as well as the inlet opening 22 and the discharge opening 32, may each be located in a different cross section (perpendicular to axis Z).
[0040] The flow geometry is substantially altered by the singularity mentioned above, and thus also by the flow rate, if this is altered by the geometry of the elements. The geometry and flow rate of the elements of device 2 thus act synergistically to obtain such flow geometry. In addition, this allows a continuous release of platelets P from megakaryocyte cells Mk with improved efficiency compared to known devices. The reader will return to this point later.
[0041] In this regard, as mentioned above, the system 1 is provided with a pumping device 60 (see FIG. 1b). The pumping device 60 is in fluid communication with the platelet release reservoir 10. This allows the fluid F contained in the reservoir 10 to be displaced. The displacement of the fluid can be due to a collapse (pressure drop) in the device 2, but also due to a fluid ejection, as will be seen in more detail later. The important point here is that the fluid F can flow at a higher velocity than it would have in the absence of the pumping device 60. The pumping device 60 is for example a vacuum pump or generally any device suitable for generating a collapse (pressure drop) or an ejection of a fluid in the device 2. For example, the pumping device 60 is a vane pump, but this is in no way intended to limit the scope of the invention.
[0042] Alternatively, the pumping device 60 may be arranged in the flow direction upstream of the first fluid connection element 20, preferably the source reservoir 40. In this regard, a pumping device 60 using fluid movement or excess pressure in the reservoir 40 may be provided. In this configuration, the fluid F is discharged in the desired flow direction and flows successively through the constriction 24, the inlet opening 22, the reservoir 10 and the outlet opening 32. This is adapted to the flow geometry resulting from each singularity. However, the use of a fluid movement pumping device 60 (gear pump, peristaltic pump, etc.) may be detrimental to the release of platelets, since it almost breaks down the megakaryocyte cells even before the process begins. The use of this type of pumping device 60 is not essential, since a discharge type device may also be considered. In general, any type of pumping device 60 may be used, with the possible exception of a fluid movement pump.
[0043] The pumping device 60 can be in fluid communication with the reservoir 10 by means of the second fluid connection element 30. Preferably, the second fluid connection element is arranged in the receiving reservoir 50. Such an arrangement results in the pumping device 60 being arranged downstream of the second fluid connection element 30 in the direction of flow of the fluid F. This allows to make the most of the singularities of the device 2, improving the process of forming vortex disturbances inside the reservoir 10, in particular its cavity 14.
[0044] In this respect, we now return to the discharge section 34 of the second connecting element 30. Advantageously, the second connecting element 30 may diverge from the discharge opening 32, but this is not essential. In this way, it is possible to create vortex disturbances inside the reservoir 10. It should be noted that the flaring of the discharge section 34 is due to the fact that its cross section diverges from the opening 32 that discharges the fluid in the direction of the pumping device 60 (i.e. in the direction of flow). The flaring of the discharge section 34 allows the pumping device 60 to move the fluid more efficiently when it is placed downstream of the second connecting element 30. This is simply because a pumping pump would not be efficient if the second connecting element 30 had a cross-sectional area equal to the cross-sectional area of the discharge opening 32 over its entire length, which is defined as the distance between the discharge opening 32 and the other end of said second element 30. In practice, as mentioned above, the discharge opening 32 has a diameter of at most 1 mm. This flaring is therefore of no importance other than to allow for more efficient suction.
[0045] The system 1 further comprises a power supply module 62 for the pumping device 60. The power supply module 62 allows the pumping device 60 to act as a motor and move the fluid F. In addition, the power supply module 62 allows the power delivered by the pumping device 60 to be adjusted, as well as any other useful parameters that will be understood by those skilled in the art. Furthermore, the power supply module 62 is preferably configured such that the power delivered by the pumping device 60 allows the displacement speed of the fluid F inside the system 1 to be adjusted, so that a flow rate of the fluid F of 37 mL / min to 120 mL / min or more can be obtained. However, as will be seen below, this is not the only parameter that affects the flow rate of the fluid. Furthermore, the system 1 may be equipped with a flow meter for controlling the flow rate of the fluid inside the reservoir 10 as a function of the power delivered by the power supply module 62. As an example, such a flow meter may be located between the source reservoir 40 and the reservoir 10. Furthermore, the power supply module 62 does not have to be located very close to the pumping device 60. It may be removed.
[0046] The system 1 further comprises a programming system 70 configured to control the power supply module 62 for the pumping device 60 to implement one or more platelet release sequences implemented to generate a continuous flow of fluid F between the inlet opening 22 and the outlet opening 32 and vortex disturbances inside the reservoir 10 to cause fragmentation of cytoplasmic extensions Ck of megakaryocyte cells Mk. The programming system 70 comprises at least one or more processors adapted to execute a program to implement the platelet release sequences. As explained below, the platelet release sequences may be varied in duration, number, etc. It is noted, however, that while the power supply module 62 may be controlled by such a programming system 70 for industrial applications, it may also be controlled manually by an operator.
[0047] 2a-2d, in the second and third embodiments of the present invention, the system 1 comprises, in addition to the first device 2, a number of further devices 2' or 2". The other devices 2' and 2" are identical to the device 2 described above. The dotted arrowed lines indicate the direction of movement of the fluid F in the system.
[0048] In a second embodiment of the system 1 according to the invention, shown in figures 2a to 2c, the device 2 is connected in series (series) to another device 2'. The devices 2, 2' are in fluid communication with each other. Preferably, the number of further devices 2' is between 1 and 4, such that the total number of devices 2, 2' is between 1 and 5. Such a configuration makes it very advantageously possible to greatly increase the number of singularities with the system 1 and thus to further improve the efficiency of platelet release. In fact, this is multiplied by the number of turbulences inside the system 1 and the number of other devices 2', so that the efficiency of platelet release increases every time the fluid F passes through another device 2'.
[0049] An example of one embodiment of such an assembly is shown in FIG. 2b. It comprises five devices 2, 2' mounted in series. The reservoir 10', the opening 16' (opening 18' is opposite and not visualized) are distinguished. The reservoirs 10' have an unobstructed cuboid shell, which has a cavity 14 of any desired shape. Here the reservoirs 10' are spherical. In the embodiment shown the reservoirs 10' are provided with a chimney 9' to degass air bubbles, although this is not essential. The connection elements 20', 30', at least their respective parts 24', 34' and the openings 22', 32' are formed in the assembly part, which are located on both sides of the reservoir 10'. The openings 22', 32' are not aligned, i.e. they are offset from each other in the direction of flow of the fluid F with respect to the device 2'.
[0050] In this respect it may also be mentioned that the one or more reservoirs 10, 10', the aforementioned assembly and connection elements 20, 20', 30, 30' may be manufactured by any suitable manufacturing method known in the prior art. In this case, the devices 2, 2' were manufactured by 3D printing and assembled by screwing. In this respect, the devices 2, 2' may be equipped with connecting means allowing their assembly. Preferably, these connecting means are made of polyetherimide (PEI) resin, or of a photopolymerizable resin (such as those used in orthodontic appliances). Preferably, this is a material according to the Pharmacopoeia of the country in which the system 1 according to the invention is to be used. The materials may be certified by the ANSM (Agence Nationale de Securite du Medicament et des Produits de Sante, French drug regulatory agency), the EMA (European Medicines Agency, European Medicines Agency, the PMDA (Pharmaceutical and Medical Devices Agency, Japan) or the FDA (Food and Drug Administration, United States) and / or the USP (United States Pharmacopoeia, United States Pharmacopeia, United States), etc. For example, for use in the United States, the device may be made from a biocompatible material that is preferably classified as USP VI (VI refers to USP class). Class testing according to the USP is one of the most common test methods for determining the biocompatibility of materials. There are six classes in the USP, with VI being the most stringent. Class VI testing is intended to ensure that there are no adverse reactions or long-term physical effects caused by chemicals released from the plastic. Due to their specificity and the fact that the device 2' is closed, they are particularly well suited to the handling of fluids specific for medical applications.
[0051] Such a configuration is also advantageous in that it improves the efficiency of the system while being optimally positioned. Indeed, instead of providing a pumping device 60 and a power supply 62 for each device 2, 2', these elements are shared by two, three or more devices 2, 2'. Indeed, while the pumping device 60 is in fluid communication with a first device 2 by means of the second fluid connection element 30 of said first device 2, as has been seen up to now, the other devices 2' are directly connected to the first connection element 20, 20' of the device 2, 2' preceding the other devices 2'. In other words, only the first device 2 is connected to the pumping device 60.
[0052] Consider for example a first other device 2' that is directly connected to a first device 2. The second fluid connection element 30' of said first other device 2' is in fluid communication with said first fluid connection element 20 of said first device 2. Preferably, this fluid communication is direct. It is therefore in indirect fluid communication with the pumping device 60 via the first device 2. Now consider a second other device 2' that is directly connected to the first other device 2'. The second fluid connection element 30' of said second other device 2' is in fluid communication with said first fluid connection element 20' of said first other device 2'. This also applies to other consecutive devices 2'.
[0053] Other types of assemblies (i.e., connection of the pumping device 60 to the devices 2, 2') can be envisaged to connect the devices 2, 2' in series (series) while respecting the inventive concept of the present invention.
[0054] It should be noted that, similar to what has been identified for the first embodiment, the system 1 according to the second embodiment comprises, in addition to the pumping device 60, a power supply module 62 for the pumping device 60 and an associated programming system 70. The flow geometry is not modified in such a system 1. In fact, this is maintained since the flow rate is propagated to all devices 2′ instead of a collapse or drain occurring in the circuit of a single device 2.
[0055] Depending on the pumping device 60 used, it may then be necessary to adapt the suction or ejection force, or more precisely to increase it, so as to obtain a sufficient displacement of the fluid for the most distant device 2'. However, if the suction or ejection force is too high, the efficiency of the platelet release may be adversely affected, since the efficiency is only optimal within a defined range of the fluid flow rate and therefore of the suction or ejection force. It is therefore appropriate to make such adaptations according to this constraint if the pumping device 60 used does not allow to maintain a constant pressure in the system 1. Most pumping devices currently available on the market generally allow to avoid such problems.
[0056] In a similar manner as mentioned above for the pumping device 60, the power supply module 62 and the programming system 70, it is also possible to provide only a single source reservoir 40 and a single receiving reservoir 50 for the entire system 1, regardless of whether this system 1 comprises one device 2 or, if applicable, multiple devices 2. Such an embodiment is for example shown in FIG. 2c. In this exemplary embodiment, the source reservoir 40 and the receiving reservoir 50 consist of flexible bags. The source reservoir 40 is in fluid communication with the other device 2′ that is the most upstream (i.e. the furthest away from the first device 2 in the fluid circuit). As for the receiving reservoir 50, like the pumping device 60, it is in fluid communication with the first device 2 by means of the second fluid connection element 30. It is noted that advantageously, the pumping device 60 can be arranged in the receiving reservoir 50.
[0057] In a third embodiment of the invention shown in FIG. 2d, the system 1 comprises devices 2, 2″ connected in parallel, i.e. a first device 2 is connected in parallel with another device 2″. In this configuration, the devices 2, 2″ are not connected to each other. In other words, the devices are independent of each other. Each device 2, 2″ therefore operates independently of the other devices. The preferred number of one or more devices 2″ is not limited. The greater the number of devices 2″, the greater the amount of fluid to be processed can be. For example, for a system 1 comprising three devices 2, 2″ connected in parallel, it is possible to process about 3 liters of fluid F per hour, thus giving the invention a conceivable advantage over devices known in the prior art. This configuration makes it possible to adapt the number of devices 2, 2″ when operating according to the volume of fluid F to be processed. A source reservoir 40 of a larger volume can be provided, but this is not required. Alternatively, means for continuously delivering the fluid to be processed can be provided.
[0058] In any case, as in the alternative embodiment of Fig. 2b, the pumping device 60, the power supply module 62 and the programming system 70 are mutual for all devices, except in this case the pumping device 60 may be placed in fluid communication with all devices 2, 2'' by one set of connections. Other types of assemblies may be envisaged for mounting the devices 2, 2'' in parallel (parallel) while respecting the inventive concept of the present invention.
[0059] Moreover, the system 1 of the present invention may be adapted to integrate additional functions by overlapping the inventive concept of the present invention, for example, a tube having a Y-shape may be provided at the inlet of the reservoir 10, which allows the circulation and mixing of two fluids F inside the reservoir 10, which is configured to generate vortex disturbances, as will be seen.
[0060] The invention further relates to a method 5 for releasing platelets P from a fluid F comprising megakaryocyte cells Mk comprising cytoplasmic extensions Ck. The method 5 according to the invention makes it possible to fragment the megakaryocytes Mk and / or the cytoplasmic extensions Ck in order to release the platelets, as will be explained in detail in the following sections. In this respect, the method 5 is implemented by the system 1 as previously described.
[0061] 3a and 3b, in a first step 100 of the method 5, a fluid F containing megakaryocytes Mk is provided. Preferably, the fluid F is stored in a source reservoir 40 provided for this purpose. The fluid F in question is, for example, a fluid taken from a patient, in particular from the patient's bone marrow, or a fluid obtained by cell culture. In any case, this fluid F contains megakaryocytes Mk and platelets can be released from this megakaryocytes Mk. However, it should be noted that whatever the fluid F, the megakaryocytes Mk are suspended in said fluid F and that the megakaryocytes are distributed differently depending on the viscosity of the fluid.
[0062] Considering the industrial quantities of fluid F that can be processed and the associated platelets that can be released, a preliminary cell culture step can be considered with the aim of obtaining the desired quantities of fluid F and precursors (i.e. megakaryocytes). The purpose of this cell culture step is to allow the maturation of megakaryocytes Mk and their expansion (i.e. their proliferation). French patent document FR 3039166 describes the cell culture process in more detail.
[0063] For example, the megakaryocyte Mk used in the fluid F is a megakaryocyte derived from an immortalized or non-immortalized CD34+ progenitor cell. Such a pre-culture process of megakaryocyte Mk may include two stages lasting a total of 11 to 17 days. During the first stage lasting 5 to 9 days, the megakaryocyte Mk is cultured with a mixture containing, for example, the following agents: serum-free medium, a cytokine cocktail containing TPO, IL-6 and IL-9, and an AhR antagonist, and LDL (a low-density lipoprotein intended to stimulate the proliferation of CD34+ cells and to commit these cells to the pathway of megakaryocytopoiesis). AhR advantageously stimulates the maturation of the megakaryocyte Mk. During the second stage of this culture process lasting approximately 6 to 8 days, the obtained cells are cultured with a mixture of SR1 and thrombopoietin, TPO, and optionally other agents as listed above with reference to the first stage. It should be noted that the obtained cells include, but are not exclusive to, megakaryocytes. In addition, it should be noted that not all cells will give rise to megakaryocytes. These steps may continue for longer or shorter periods of time depending on the number of cells desired, the agents used, etc.
[0064] This preliminary step is not the subject of the present invention and does not form part of it, so it will not be further described. The present invention is limited to proposing a method for releasing platelets from a fluid F, without proposing a method that includes any culturing step. In any case, at the end of this cell culturing step, proplatelet megakaryocytes (i.e. megakaryocytes provided with proplatelets) are obtained. For the sake of simplicity, these are simply called megakaryocytes Mk in the present invention. Such cells are shown in FIG. 4a. These cells comprise megakaryocytes, with proplatelets forming extensions from the megakaryocytes. The cytoplasmic extensions are supported by a network of microtubules and end in button-like platelets that preform what will become platelets. The fluid F provided in step 100 comprises such proplatelet megakaryocytes.
[0065] 3a and 3b, method 5 follows step 100 and includes step 200 of powering the pumping device 60 to generate a depression (pressure drop) or drainage at the outlet of the second fluid connection element 30.
[0066] During step 200, the power of the power supply module 62 for the pumping device 60 can be set to adjust the suction or ejection power. In particular, it must be adjusted so that the resulting flow rate of fluid F is 37 mL / min to 120 mL / min or more. It should be noted that depending on the material from which the device of the system 1 according to the invention is made, the fluid flow rate can be significantly increased. This is the optimal flow rate range for obtaining maximum platelet release efficiency with the method according to the invention. The applied power essentially depends on the material used for the pumping device 60.
[0067] During step 300, the programming system 70 is controlled to initiate one or more platelet release sequences as defined above. Advantageously, the programming system 70 is capable of controlling the power supply module 62. The programming system 70 also allows for control of the overall time and number of platelet P release sequences. The platelet release sequences can continue for as long as desired by the user to process a desired volume of fluid.
[0068] When the programming system 70 described in the previous section is operated with the powered pumping device 62, a collapse (depressurization) or, depending on the configuration, a discharge occurs in one or more of the devices 2, 2', 2". "Collapse" means that the pressure in one or more of the devices 2, 2', 2" drops below atmospheric pressure, i.e. that they are subjected to a relative vacuum. "Discharge" corresponds to the fact of moving the fluid F by a discharge pump, for example an ejector or a compressor. As a result of this collapse (depressurization) or this discharge, a continuous flow (i.e. displacement) of the fluid F occurs in the system 1 from the source reservoir 40 to the receiving reservoir 50. It is noted that preferably, the suction or discharge force of the pumping device 60 is also kept constant during the method 5, so that the collapse (depressurization), the discharge rate, if appropriate, and the flow rate of the fluid F remain substantially constant. However, this condition does not prevent power variations during the practice of the method within limits that make it possible to obtain optimal platelet release efficiency.
[0069] As soon as a collapse (depressurization) or discharge occurs in one or more of the systems 2, 2', 2'', without further action in the programming system 70, the fluid passes through different stages (i.e. 302, 304 and 306) which occur successively as long as the collapse (depressurization) or discharge is maintained. These stages are a direct result of fluid displacement in one or more of the systems 2, 2', 2''. Stage 302 corresponds to the stage before the fluid F enters the reservoir 10, stage 304 corresponds to the stage when the fluid F is present in the reservoir 10 and stage 306 corresponds to the stage after the fluid F has been sucked out of the reservoir 10. In other words, stages 302, 304 and 306 actually occur simultaneously, since while one part of the fluid F is being treated, another part of the fluid F is being treated in the reservoir 10 at the same time, and another part will be treated upstream of the reservoir 10 along the fluid circuit (i.e. in the first connection element 20 or in the source reservoir 40).
[0070] During step 302, fluid F is aspirated through the first fluid connection element 20. As the pressure inside the device remains constant, the velocity of fluid F increases as it passes through the constriction 24, due to the very fact that said constriction 24 is flared. Fluid F is then expelled through the inlet opening 22 into the reservoir 10. A singularity due to the sudden cross-sectional expansion present at the inlet opening 22 / reservoir 10 interface causes the fluid F to decelerate as it enters the reservoir 10.
[0071] During stage 304, the fluid F flows through the reservoir 10 and is subject to the collapse or discharge generated by the pumping device 60 within the limits of the cavity 14. In fact, the fluid continues to move due to this collapse or discharge, although it is slowed down by the singularity present at the opening 22 / reservoir 10 interface. This allows the fluid to circulate, such as in the form of vortex disturbances, without the fluid flowing directly out of the reservoir. In fact, the system 1 is configured such that the residence time of the fluid F in the reservoir 10 is sufficient to generate disturbances. As explained above, the large size of the singularity of the reservoir 10 relative to the discharge opening 32 ensures a sufficient residence time. The residence time can also be increased, but only to a small extent, by advantageously offsetting the position of the inlet opening 22 relative to the discharge opening 32 in the path of the fluid F, as explained below.
[0072] Under these conditions, vortex disturbances of approximately the same size as megakaryocytes are created. These vortex flows make it possible to fragment the megakaryocytes Mk and their cytoplasmic extensions Ck (proplatelets), resulting in the release of platelets P. At the same time, other products Dk resulting from the fragmentation of the megakaryocytes are produced. These products are proplatelet fragments, intact bodies of megakaryocytes Mk, or cytoplasmic fragments. Since the fluid F is processed successively in time for each platelet release sequence, the above phenomenon is reproduced successively and platelets are released successively. In summary, the fluid F entering the reservoir 10 contains megakaryocyte cells Mk with their cytoplasmic extensions, while the fluid F leaving the reservoir 10 essentially contains platelets P and other products Dk. In this regard, the use of a system 1 with successive devices 2, 2', as shown in Figures 2a to 2c, advantageously makes it possible to reduce the proportion of megakaryocytes that are still unprocessed according to method 5. Each time the fluid F circulates in the device 2', this fluid F is subjected to a disturbance. It must therefore be borne in mind that the efficiency of the series system 1 is higher compared to a system 1 with a single device 2.
[0073] During stage 306, fluid F with platelets P and other products resulting from the fragmentation of megakaryocytes is aspirated through the outlet opening 32 and more generally through the second fluid connection element 30. In this way, fluid F reaches the receiving reservoir 50 and, if present, the pumping device 60.
[0074] During step 400 , one or more sequences are stopped by powering off the power supply module 62 using the programming system 70 .
[0075] These steps occur analogously in any other devices 2' and / or 2'' present in the system 1 according to the invention.
[0076] To release the platelets, the flow rate of the fluid should advantageously be between 37 and 120 mL / min or more. These flow rate values are average values representing the average of 6 measurements. Figure 5a shows the release of the platelet count of several calibration tubes (BD Trucoun® Tubes) or of counting tubes equal to 5000, as a function of the relative vacuum generated by implementing the method according to the invention (grey bars) and by the pipette (black bars). The relative vacuum is in particular expressed in kilopascals (kPa). When no collapse or ejection occurs in one or more of the devices 2, 2', 2'' the platelet release efficiency remains very low (very light grey). With a relative vacuum equal to -10 kPa, a minimum value of 37 mL / min is obtained as mentioned above. With such a relative vacuum the platelet release efficiency increases and the number of released platelets exceeds 10,000 per 5000 tubes. This efficiency of platelet release is still relatively low. As the relative vacuum increases, the efficiency of platelet release increases. When the relative vacuum is equal to -30 kPa, the above mentioned value of 120 mL / min is obtained. The number of platelets released is more than 20,000 per 5,000 megakaryocyte tubes. As shown in FIG. 5a, the platelet release efficiency obtained is close to that obtained using a conventional manual pipette, and may even be higher. This shows the importance of the depression (depressurization) or fluid drainage occurring in the system 1 to obtain a satisfactory release efficiency. In the exemplary embodiment shown here, when the relative vacuum is -30 kPa, it can be increased to more than -30 kPa, i.e. up to 50 kPa. The fluid flow rate obtained is much higher than 120 mL / min.
[0077] This is due to the characteristics of the device(s) 2, 2', 2" used in the exemplary embodiment of the invention. Indeed, to regulate the flow rate, a compromise must be made between the suction or discharge force of the pumping device 60, the size of the inlet opening 22 and the size of the outlet opening 32, as well as the surface condition of the element(s) of the device(s) 2, 2', 2" through which the fluid F actually passes, which is within the limits of the invention. Given this last aspect, the more the surface condition (microscopic surface roughness, surface roughness, etc.) has a restrictive effect on the fluid F, the more the fluid F will slow down and vice versa. To obtain a higher platelet release efficiency, for example the surface condition can be adjusted. This can be done by modifying the material used to manufacture the element(s) of the device(s) 2', 2" through which the fluid F flows, by using other manufacturing methods that allow the control of the structure on the micrometer scale, or even by pouring compounds such as, for example, plasma or albumin into the chamber.
[0078] Figure 5b shows the analysis of the functionality of the platelets obtained at a pressure of -30 kPa for native platelets (hollow rods) and for cultured platelets (solid rods). At this relative vacuum, approximately 8% of native platelets and approximately 10% of inactivated cultured platelets express the glycoprotein GPIIb / IIIa. Approximately 12% of native platelets and approximately 16% of cultured platelets activated with a CRP-type agonist (collagen-related peptide) express the glycoprotein GPIIb / IIIa. Finally, approximately 30% of native platelets and approximately 22% of cultured platelets activated with a TRAP-type agonist (thrombin receptor-activating peptide) express the glycoprotein GPIIb / IIIa. The platelets obtained by the method according to the invention are therefore well activated and consequently functional. [Explanation of symbols]
[0079] 1 System 2 (First) Device 2´ Other devices 2´´ Other devices 10 Platelet release reservoir 16 First opening 18 Second Opening 20 First fluid connection element 22 Injection opening (injection orifice) 24 Stenosis 30 Second fluid connection element 32 Discharge opening (discharge orifice) 34 Expanding part (discharge part) 40 Supply Reservoir 50 Receptor Reservoir 60 Pumping Devices 62 Power Supply Module
Claims
1. A system (1) for releasing platelets from a fluid (F) that contains, in particular, megakaryocyte cells (Mk) that contain cytoplasmic extensions (Ck), the system (1) comprising: a device (2) comprising: a platelet release reservoir (10) comprising a first opening (16) and a second opening (18); a first fluid connection element (20) attached at the level of said first opening (16) and adapted to inject said fluid (F) into said reservoir (10), said first fluid connection element (20) comprising an opening (22) for injecting said fluid into the platelet release reservoir (10) and a portion (24) narrowing towards said opening (22), with a portion of sudden expansion of cross section being present between said injection opening (22) and said reservoir (10); and, a second fluid connection element (30) mounted at the level of said second opening (18), said second fluid connection element (30) comprising an opening (32) for discharging the fluid; A device (2) comprising: a device (60) for pumping a fluid (F), in fluid communication with said reservoir (10) by means of a second fluid connection element (30) or a first fluid connection element (20), a power supply module (62) for said pumping device (60); a programming system (70) configured to control the power supply module (62) for the pumping device (60) to generate a continuous flow of the fluid (F) between the inlet opening (22) and the outlet opening (32) and to implement one or more platelet release sequences designed to generate vortex disturbances inside the reservoir (10) causing fragmentation of cytoplasmic extensions (Ck) of megakaryocyte cells (Mk); A system comprising:
2. The system of claim 1 , wherein the constriction (24) is conical.
3. 2. The system of claim 1, wherein the first fluid connection element (20) comprises a longitudinal axis (X1) and the second fluid connection element (30) comprises a longitudinal axis (X2), the longitudinal axes (X1, X2) being intersecting or parallel and spaced apart by a non-zero distance (d).
4. The system according to any one of claims 1 to 3, wherein the injection opening (22) has an opening diameter of less than 1 mm and the ratio of the opening diameter of the injection opening (22) to the cross-sectional width of the reservoir (10) is between 0.02 and 0.
1.
5. 5. The system of claim 4, wherein the ratio of the opening diameter of the injection opening (22) to the cross-sectional width of the reservoir (10) is 0.
05.
6. The system according to any one of claims 1 to 5, wherein the discharge opening (32) has an opening diameter of less than 1 mm and the ratio of the opening diameter of the discharge opening (32) to the cross-sectional width of the reservoir (10) is between 0.02 and 0.
1.
7. 7. The system of claim 6, wherein the ratio of the opening diameter of the discharge opening (32) to the cross-sectional width of the reservoir (10) is 0.
05.
8. The system according to any one of the preceding claims, wherein the reservoir (10) has a spherical shape.
9. a source reservoir (40) for storing a fluid (F), connected to the first fluid connection element (20) for supplying the reservoir (10); and a reservoir (50) for receiving a fluid (F), connected to said second fluid connection element (30) for recovering said fluid intended to be aspirated from said reservoir (10); The system according to any one of claims 1 to 8, comprising:
10. The system of claim 9, wherein the pumping device (60) is disposed within the receiving reservoir (50).
11. The system of any one of claims 1 to 10, wherein the second fluid connection element (30) further comprises a portion (34) extending from the opening (32) for discharging fluid towards the pumping device (60).
12. A system (1) according to any one of the preceding claims, comprising at least one other device (2''), The other device (2 ″) is a platelet release reservoir (10'') with a first opening (16'') and a second opening (18''); a first fluid connection element (20'') attached at the level of said first opening (16'') and adapted to inject said fluid (F) into the interior of said reservoir (10'', said first fluid connection element (20'') comprising an opening (22'') for injecting said fluid and a first constriction (24'') making it possible to accelerate said fluid (F), said first constriction (24'') opening onto said injection opening (22'', and a second fluid connection element (30'') mounted at the level of said second opening (18'') and comprising an opening (32'') for discharging the fluid; Equipped with A system, characterized in that the other device (2'') is arranged parallel to the first device (2) and is connected to the pumping device by a second fluid connection element (30'') of the other device.
13. A system (1) according to any one of the preceding claims, comprising at least one other device (2'), The device (2') comprises: a platelet release reservoir (10') with a first opening (16') and a second opening (18'), a first fluid connection element (20') attached at the level of said first opening (16') and adapted to inject said fluid (F) into the interior of said reservoir (10'), said first fluid connection element (20') comprising an opening (22') for injecting said fluid and a first constriction (24') making it possible to accelerate said fluid (F), said first constriction (24') opening onto said injection opening (22'); and a second fluid connection element (30') mounted at the level of said second opening (18') and comprising an opening (32') for discharging the fluid; Equipped with The system is characterized in that the other device (2') is arranged in series with the first device (2) and the second fluid connection element (30') of the other device (2') is in fluid communication with the first fluid connection element (20) of the first device (2).
14. A method (5) for releasing platelets (P) from a fluid (F) notably containing megakaryocyte cells (Mk) comprising cytoplasmic extensions (Ck), said method being carried out by a system (1) according to any one of claims 1 to 13 and comprising the following steps: providing a fluid (F) containing megakaryocyte cells (Mk) suspended in said fluid (F), said megakaryocyte cells (Mk) comprising cytoplasmic extensions (Ck); Providing (200) power to a pumping device (60); controlling (300) a programming system (70) to initiate one or more platelet release sequences; Including, The or each said platelet release sequence comprises: The method is characterized in that it is carried out by generating a continuous flow of a fluid (F) between an inlet opening (22) and an outlet opening (32) and generating vortex disturbances inside a reservoir (10) to cause fragmentation of cytoplasmic extensions (Ck) of megakaryocyte cells (Mk).
15. The method according to claim 14, wherein during said step (200) a relative vacuum of between -10 kPa and -50 kPa is generated in said device (2, 2', 2'').
Citation Information
Patent Citations
Method for preparing platelets using reciprocating stirring device
WO2017077964A1
Method for producing platelets
WO2018164040A1
Platelet production method and apparatus and method for determining operating conditions in platelet production apparatus
WO2019009364A1
